Literature DB >> 7908035

Sennoside-induced secretion is not caused by changes in mucosal permeability or Na+,K(+)-ATPase activity.

E Leng-Peschlow1.   

Abstract

The effect of sennosides (50 mg kg-1) on the rat colon in-situ was studied 6 h after oral treatment when the laxative effect was maximal. In a second experiment, rhein (4 x 10(-3) M), an active sennoside metabolite, was administered into the lumen of the colon for 1 h. Both sennosides and rhein reduced net H2O and Na+ absorption or reversed it to net secretion. Paracellular permeability, as measured using erythritol as a small marker molecule, was increased 2- to 3-fold; permeability to a large molecule, PEG 1000, was unchanged. The activity of Na+,K(+)-ATPase in the colon mucosa was not affected. There was no damage of the epithelial cells as determined by lactic acid dehydrogenase release. These results indicate that neither inhibition of Na+,K(+)-ATPase nor damage of the colon epithelium are involved in the secretory effect of sennosides or rhein. The increased paracellular permeability of small molecules fits into the concept of stimulation of active chloride secretion by sennosides, which is electrochemically and osmotically balanced by an increase in Na+ and H2O flow via the paracellular pathway.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7908035     DOI: 10.1111/j.2042-7158.1993.tb05633.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

1.  Diuretics-assisted treatment of chronic laxative abuse.

Authors:  Yuichi Shirasawa; Michio Fukuda; Genjiro Kimura
Journal:  CEN Case Rep       Date:  2014-03-26

2.  The anthraquinone derivative Emodin ameliorates neurobehavioral deficits of a rodent model for schizophrenia.

Authors:  M Mizuno; H Kawamura; N Takei; H Nawa
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

Review 3.  Rhein: A Review of Pharmacological Activities.

Authors:  Yan-Xi Zhou; Wei Xia; Wei Yue; Cheng Peng; Khalid Rahman; Hong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-22       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.